This Article Full Text Full Text (PDF) All Versions of this Article: 1535-7163.MCT-07-2141v1 7/4/972    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Lubet, R. A. Articles by Grubbs, C. J. PubMed PubMed Citation Articles by Lubet, R. A. Articles by Grubbs, C. J. Related Collections Clinical Intervention Clinical Intervention:Molecular Targeted Drugs

Research Articles: Therapeutics, Targets, and Development

Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes

¹ Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland; ² Department of Surgical Oncology, University of Illinois at Chicago, Chicago, Illinois; ³ The Hormel Institute, Austin, Minnesota; ⁴ Department of Dermatology, University of Minnesota, Minneapolis, Minnesota; and ⁵ Departments of Surgery and Genetics, University of Alabama at Birmingham, Birmingham, Alabama

Requests for reprints: Ronald A. Lubet, National Cancer Institute, Executive Plaza North, Suite 2110, 6130 Executive Boulevard, Bethesda, MD 20852. Phone: 301-594-0457; Fax: 301-402-0553. E-mail: lubetr{at}mail.nih.gov

Abstract

The ability of the epidermal growth factor receptor inhibitor gefitinib (Iressa) to prevent/treat methylnitrosourea (MNU)-induced mammary cancers and to modulate biomarkers in female Sprague-Dawley rats was examined. Rats were given a single dose of MNU (75 mg/kg body weight) at 50 days of age. In the prevention studies, continual treatment with Iressa at 10, 3, or 1 mg/kg body weight per day beginning 5 days after MNU reduced tumor multiplicity by 93%, 43%, and 20%, respectively. Treatment of rats bearing small palpable cancers with Iressa (10 mg/kg body weight per day) resulted in the complete regression of 70% of the tumors. Short-term treatment of tumor-bearing rats with Iressa caused decreases in cell proliferation and phosphorylated epidermal growth factor receptor and increases in apoptosis. To examine treatment regimens that might decrease the skin toxicity associated with Iressa, both intermittent treatments and combinations of lower doses of Iressa with other effective agents were evaluated. Treatment with Iressa (10 mg/kg body weight per day) continually or intermittently (either "3 weeks on/3 weeks off" or "4 days on/3 days off") reduced cancer multiplicity by 91%, 24%, and 68%, respectively. However, all regimens reduced tumor weights >85%. Finally, combining suboptimal doses of Iressa with suboptimal doses of vorozole (an aromatase inhibitor) or targretin (a retinoid X receptor agonist) yielded greater chemopreventive efficacy than any of these agents given alone. [Mol Cancer Ther 2008;7(4):972–9]

Grant support: National Cancer Institute grants NO1-CN-25003, NO1-CN-15123, and NO1-CN-43301.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 9/27/07; revised 1/17/08; accepted 1/25/08.